FDA Approves Juvmo, a New Parkinson’s Treatment Designed to Improve Motor Symptom Control
The once-daily oral medication, developed by AbbVie, targets dopamine receptors differently from existing therapies and offers a new treatment option for adults living with Parkinson’s disease.
The U.S. Food and Drug Administration (FDA) has approved tavapadon, marketed under the brand name Juvmo, as a new treatment for adults with Parkinson’s disease. Developed by AbbVie, the once-daily oral medication is designed to help manage motor symptoms and can be taken with or without levodopa, a standard treatment for the disease.
According to AbbVie, Juvmo is expected to become commercially available in the United States in October 2026. Its approval introduces a new approach to managing Parkinson’s symptoms by targeting dopamine receptors that differ from those addressed by many existing dopamine agonists.
For people living with Parkinson’s and their care teams, the approval adds another option to a treatment landscape in which maintaining symptom control while minimizing side effects remains an important challenge.
Understanding Parkinson’s Disease and Its Treatment Challenges
Parkinson’s disease is a progressive neurological disorder characterized by the loss of dopamine-producing cells in the brain. Dopamine is a neurotransmitter that plays a critical role in regulating movement, coordination, and other functions. As dopamine levels decline, people with Parkinson’s may experience symptoms such as tremors, muscle stiffness, slowed movement, and difficulties with balance and coordination. Levodopa remains a cornerstone of Parkinson’s treatment. The medication helps replenish the brain’s supply of a substance used to produce dopamine, improving movement and helping many people manage their daily activities.
However, as the disease progresses, treatment can become more complicated. The loss of dopamine-producing cells may contribute to fluctuations in symptom control, and some patients require adjustments to their medication regimens. Long-term levodopa treatment can also be associated with involuntary movements known as dyskinesia. Dopamine agonists offer another approach. Rather than supplying the brain with material to make dopamine, these medications mimic dopamine’s activity by stimulating its receptors. Many existing dopamine agonists primarily target D2 and D3 receptors.
Although these treatments can help manage symptoms, their effectiveness and tolerability vary among individuals. This has created a continuing need for therapies that target dopamine signaling through different pathways.
How Juvmo Works Differently
Juvmo belongs to a class of medications known as dopamine agonists, but it has a distinct mechanism of action. The medication selectively targets D1 and D5 dopamine receptors, rather than focusing primarily on the D2 and D3 receptors targeted by many existing dopamine agonists. According to AbbVie, this different approach is intended to provide sustained motor symptom control and offer clinicians another way to tailor treatment to individual patient needs. The company describes Juvmo as the first and only selective D1/D5 dopamine agonist approved for Parkinson’s disease. “The approval of Juvmo marks the first dopaminergic breakthrough for Parkinson’s disease in decades,” said Roopal Thakkar, MD, AbbVie’s executive vice president of research and development and chief scientific officer.
While the approval represents a new mechanism in Parkinson’s treatment, its significance for individual patients will depend on factors such as symptom severity, treatment response, tolerability, and the other medications they take.
What the TEMPO Clinical Trials Found
The FDA’s approval was supported by data from AbbVie’s TEMPO clinical development program, which included studies involving people with different stages of Parkinson’s disease.
The program included three main placebo-controlled trials:
TEMPO-1: Evaluated Juvmo in adults with early-stage Parkinson’s disease who had received minimal or no previous treatment.
TEMPO-2: Also investigated the medication in adults with early-stage disease, assessing its effects on symptoms and daily functioning.
TEMPO-3: Evaluated Juvmo against a placebo in more than 500 people with more advanced Parkinson’s disease.
According to AbbVie, the trials demonstrated that Juvmo was superior to placebo in improving Parkinson’s symptoms and patients’ ability to function in everyday life. In the early-stage studies, treatment also helped delay the initiation of levodopa, potentially offering an additional approach for managing symptoms before introducing that medication. Longer-term data from TEMPO-4, an extension study, indicated that benefits were maintained over time, according to the company.These findings contributed to the evidence supporting FDA approval. However, results from placebo-controlled trials do not establish that every patient will experience the same degree of improvement, and individual treatment outcomes may vary.
A New Option for Individualized Parkinson’s Care
Parkinson’s treatment often requires an individualized approach. Symptoms, disease progression, other health considerations, and medication side effects can all influence which therapies are appropriate.
Juvmo may offer clinicians an additional option when considering how to manage motor symptoms, either as a standalone treatment in appropriate patients or alongside levodopa. Hubert Fernandez, MD, the global principal investigator of the TEMPO trials and a professor at the Cleveland Clinic Lerner College of Medicine, highlighted the ongoing need for innovation in Parkinson’s treatment. He noted that the new therapy’s selective targeting of D1/D5 receptors could give health care providers greater flexibility when tailoring treatment to patients’ needs. Importantly, Juvmo does not replace the need for individualized medical assessment. Its role in a treatment plan will depend on the patient’s stage of disease, symptom pattern, current medications, and potential risks.
Potential Side Effects and Safety Considerations
As with other Parkinson’s medications, Juvmo has potential side effects that patients and clinicians should consider.
According to its prescribing information, commonly reported side effects include:
Nausea
Headache
Dizziness
Fatigue
Dysgeusia, or an altered sense of taste
Vomiting
Dry mouth
Anxiety
When Juvmo is taken with levodopa, additional or more frequent concerns may include dyskinesia, nausea, dizziness, headache, and orthostatic hypotension—a sudden drop in blood pressure when standing up. The prescribing information also warns that hallucinations and psychotic-like behavior can occur when Juvmo is used with levodopa. Although the medication's prescribing information lists no formal contraindications, that does not mean it is appropriate for everyone or that it is free of serious risks. Patients should review its warnings and precautions with their health care providers before starting treatment. Anyone taking Juvmo should discuss new or worsening symptoms with their clinician and should not change or discontinue prescribed Parkinson’s medications without medical guidance.
Parkinson’s Community Welcomes the Approval
The FDA’s decision has been welcomed by organizations working to improve care and advance research for people with Parkinson’s disease. Brian Fiske, PhD, chief scientist of The Michael J. Fox Foundation for Parkinson’s Research, emphasized the importance of expanding the range of available therapies.
“For people with Parkinson’s and their families, progress means having treatment options that deliver meaningful benefit in everyday life,” Fiske said. He added that each new therapy approval represents an important milestone in developing a broader treatment pipeline that can address the diverse needs of the Parkinson’s community. The foundation’s response reflects a wider priority in Parkinson’s research: developing treatments that not only address symptoms but also give patients and clinicians more choices as the disease changes over time.
What Juvmo’s Approval Means for the Future
The approval of Juvmo marks a new development in the pharmacological treatment of Parkinson’s disease. By selectively targeting D1 and D5 dopamine receptors, the medication introduces a different approach to managing motor symptoms in adults with the condition. Clinical trial findings reported by AbbVie indicate that the treatment can improve symptoms and daily functioning compared with placebo, with benefits also observed in longer-term follow-up. Its potential to delay levodopa initiation in some people with early-stage disease may also be relevant when clinicians consider treatment strategies. At the same time, questions about long-term outcomes, individual tolerability, and how Juvmo compares directly with established treatments remain important. The reported placebo-controlled trials do not, by themselves, demonstrate superiority over other active Parkinson’s medications. As the medication becomes available in the United States, discussions between patients and clinicians will help determine where it may fit into existing care plans. For the Parkinson’s community, the approval represents an additional treatment option—and another step toward addressing the varied challenges of living with a progressive neurological disease.
Medical disclaimer: This article is for informational purposes only and is not a substitute for professional medical advice. Patients should consult a qualified health care provider about treatment options and medication-related risks.
Source: